Biphasic Clinical Overview

Full energy biphasic 360 Joule technology
Stryker’s LIFEPAK® monitor/defibrillators

Key definitions

**Monophasic waveform**
(older, single direction energy delivery, higher peak current)

**Biphasic waveform**
(modern, bidirectional energy delivery, less peak current)

- **Biphasic Truncated Exponential- BTE**
  (dynamic current and duration, fixed shape)
- **Rectilinear Biphasic Waveform- RBW**
  (dynamic current and shape, short fixed duration)

**Energy expressed in joules**
(combined metric of current and voltage over time)

- **Joule** (unit of energy (J), 1 amp passing through 1 ohm for 1 sec)
- **Current** (flow of electricity measured in amps (A))
- **Voltage** (electromotive push or force measured in volts (V))
- **Duration** (interval of time measured in milliseconds)
- **Impedance** (resistance to flow of current measured in ohms)

**Clinical study** (human population)

**Experimental study** (animal population)

Optimizing conversion rates

Biphasic research has provided direction on optimizing conversion rates for the 5-11% of cardiac arrest patients who are difficult-to-defibrillate.1,2 The more efficient biphasic defibrillation waveforms still leave room to improve conversion rates.3

- No singular electrical characteristic (current, voltage or duration) of any biphasic waveform determines conversion rate.3
- The therapeutic defibrillation dose is a defined set of electrical characteristics over a defined time, measured as energy.5
- Published clinical data strongly points to an association between higher biphasic shock energy (joules) and higher conversion rates for VF/pVT and AF.1-4

**Biphasic waveforms and maximum programmed settings**

* Biphasic measurements testing at 90 ohms with the Stryker’s LIFEPAK 15 monitor/defibrillator, ZOLL X-Series monitor/defibrillator and Philips MRx monitor/defibrillator.
* Average human impedance range is approximately 70-80 ohms.
Clinical evidence

1. A large volume of published data now exists on biphasic defibrillation. It should be referenced when evaluating proven performance.
2. The data shows that at the same low energy biphasic shocks, the most widely used defibrillation waveforms (BTE and RBW) have the same conversion rates from 50J to 200J.8-12
3. The data also shows that higher energy biphasic waveforms are associated with higher conversion rates for VF/pVT and AF.1-4,19
4. The 2010 and 2015 AHA Guidelines state full energy biphasic 360J is safe for patients.3,7,14-16 High peak current is a primary cause of myocardial injury.17 Biphasic waveforms use as much as 40% less current than monophasic waveforms.

Published clinical performance
- Early manufacturer biphasic studies were done in EP labs on non-critical, short duration VF patients. All showed high conversion rates at lower shock energies. But biphasic performance in real-world cardiac arrest patients matters more.
- The Stryker biphasic waveform (BTE) has been studied in nearly 2X as many cardiac arrest patients as all other manufacturers’ biphasic waveforms combined, across a wide range of impedances.*

Low energy biphasic 50J to 200J: clinical equivalence
- From 50J to 200J, five clinical cardioversion studies showed that at the same low energies, biphasic waveforms had the same conversion rates.8-12
- Three studies compared the Stryker’s BTE (LIFEPAK 12) and ZOLL RBW (M Series®) waveforms.8-10
- Two studies compared the Philips BTE (MRx) and ZOLL RBW (M Series and R Series®) waveforms.11,12
- For each study; **same low energies = same conversion rates**

Full energy biphasic 360J: clinical advantage
- Clinical studies (VF and AF) show protocols with escalating energy to full energy 360J improves conversion rates for difficult-to-defibrillate patients.1-4
- No clinical (human) evidence exists showing low energy (150J to 200J) from any monitor/defibrillator provides equivalent or superior conversion rates when compared to full energy biphasic 360J.

The only randomized, triple-blinded dosing comparison showed higher conversion rate for VF/pVT when escalating to 360J vs. a fixed protocol.2

Conversion rate were lower when 200J was repeated for recurrent VF/pVT. All were eventually converted with 360J.2

Conversion rate probability increased in a subset of VF/pVT patients who received shocks at each energy dose. 360J had the highest cumulative rate.3

---

*These data represent the cumulative number of cardiac arrest patients in whom the VF termination efficacy (using the established definition of “removal of VF for ≥ 5 seconds”) of specific biphasic waveforms and energy levels has been reported in published papers describing either randomized or consecutive case series of OHCA or IHCA patients. Included are papers that report a VF termination rate for at least one of 1) first shocks or 2) all shocks.
Clinical Overview

### Biphasic defibrillation comparison

<table>
<thead>
<tr>
<th>Published biphasic data on cardiac arrest patients*</th>
<th>LIFEPAK monitor/defibrillators and AEDs</th>
<th>ZOLL E Series® monitor/defibrillators</th>
<th>ZOLL X Series monitor/defibrillators</th>
<th>Philips monitor/defibrillators and AEDs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Max programmed setting</td>
<td>360 Joules</td>
<td>200 Joules</td>
<td>200 Joules</td>
<td>150 Joules - AED</td>
</tr>
<tr>
<td>8 studies</td>
<td>8 studies</td>
<td>8 studies</td>
<td>8 studies</td>
<td>8 studies - ALS</td>
</tr>
<tr>
<td>11 studies</td>
<td>3 studies</td>
<td>0 studies</td>
<td>0 patients</td>
<td>200 Joules</td>
</tr>
<tr>
<td>2,808 patients</td>
<td>441 patients</td>
<td>0 patients</td>
<td>934 patients</td>
<td></td>
</tr>
<tr>
<td>Biphasic waveform type</td>
<td>BTE</td>
<td>RBW</td>
<td>RBW</td>
<td>BTE</td>
</tr>
<tr>
<td>Biphasic waveform duration</td>
<td>13.4 - 18.9 ms²</td>
<td>10 ms² (fixed)</td>
<td>10 ms² (fixed)</td>
<td>8.6 - 17 ms²</td>
</tr>
</tbody>
</table>

*These data represent the cumulative number of cardiac arrest patients in whom the VF termination efficacy (using the established definition of “removal of VF for ≥ 5 seconds”) of specific biphasic waveforms and energy levels has been reported in published papers describing either randomized or consecutive case series of OHCA or IHCA patients. Included are papers that report a VF termination rate for at least one of 1) first shocks or 2) all shocks. Based on information available in the published literature as of March 2018.

**May deliver more energy than the E Series, M Series and ZOLL AEDs. This is less than the maximum energy delivered in LIFEPAK monitor/defibrillators and LIFEPAK AEDs.

### Clinical strategies to improve conversion rates

The Critical Mass Theory is a meaningful conceptualization that can help clinicians improve conversion rates. The goal is to depolarize as much of the myocardial tissue as possible at once, placing it into a repolarized, refractory state unable to re-propagate the electrical misfires that cause VF/pVT. Two controllable factors can significantly impact this complex biological interaction.

1. **Optimize the size of the defibrillation field**

   Higher energy (J) can increase a shock’s myocardial coverage while less energy likely covers less. Data supports escalating to 360J as a mechanism to maximize conversion rates.¹⁴⁻¹⁸

2. **Optimize the vector of the defibrillation field**

   Suboptimal pad placements can also lower conversion rates. Escalating to 360J can compensate for these variations.¹⁹

### Closing points

- Science recognizes that no individual characteristic of a well-designed biphasic waveform determines conversion rate. The combined total of a shock’s electrical characteristics (energy expressed in joules), determines conversion rate.

- The data shows that at the same low energy biphasic shocks, the most widely used defibrillation waveforms (BTE and RBW) have the same conversion rates from 50J to 200J.

- Published clinical data demonstrate protocols with escalating energy to 360J improves conversion rates for difficult-to-defibrillate VF and AF patients.

- No commercially available defibrillator on the market offers equivalent strength to full energy biphasic (360J) offered by Stryker’s LIFEPAK defibrillators for both AED and manual defibrillation.
References


For further information, please contact Stryker at 800 442 1142 (U.S.), 800 668 8323 (Canada) or visit our website at strykeremergencycare.com

Emergency Care

Stryker or its affiliated entities own, use, or have applied for the following trademarks or service marks: LIFEPAK, Stryker. All other trademarks are trademarks of their respective owners or holders.

The absence of a product, feature, or service name, or logo from this list does not constitute a waiver of Stryker’s trademark or other intellectual property rights concerning that name or logo.

GDR 3336407_C
Copyright © 2020 Stryker